EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors
William O. Shaffer(Beth Israel Deaconess Medical Center), Daniel B. Costa(Beth Israel Deaconess Medical Center)
Cited by 6
Related Papers
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
|Journal of Clinical Oncology|2011|590
BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
|PLoS Medicine|2007|490
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
|Lung Cancer|2013|93
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
|JTO Clinical and Research Reports|2020|81